Login to Your Account



AML endpoint eludes Erytech's Graspa

By Michael Fitzhugh
Staff Writer

Friday, December 8, 2017

Osmotic stress, key to Erytech Pharma SA's ability to stash therapeutic enzymes inside red blood cells, was joined by market stress Friday, as investors pushed company shares more than 30 percent lower on news that a combination of its lead candidate, Graspa, and low-dose cytarabine failed to help people with AML live longer than treatment with LDAC alone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription